Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2012, Article ID 239269, 3 pages
http://dx.doi.org/10.1155/2012/239269
Case Report

Prophylactic Breast Bud Radiotherapy for Patients Taking Bicalutamide: Should This Still Be Practised for Patients with Prostate Cancer?

Department of Clinical Oncology, University College Hospital London, London NW1 2PG, UK

Received 11 June 2012; Accepted 24 July 2012

Academic Editors: J. M. Buchanich and F. Fang

Copyright © 2012 R. Lewis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. http://www.nice.org.uk/cg58.
  2. W. Zhang, A. Becciolini, A. Biggeri, P. Pacini, and C. R. Muirhead, “Second malignancies in breast cancer patients following radiotherapy: a study in Florence, Italy,” Breast Cancer Research, vol. 14, no. 2, article R38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. B. A. De Gonzalez, R. E. Curtis, E. Gilbert et al., “Second solid cancers after radiotherapy for breast cancer in SEER cancer registries,” British Journal of Cancer, vol. 102, no. 1, pp. 220–226, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Iversen, D. G. McLeod, W. A. See, T. Morris, J. Armstrong, and M. P. Wirth, “Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years,” British Journal of Urology International, vol. 105, no. 8, pp. 1074–1081, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. W. U. Shipley, D. Hunt, H. Lukka et al., “Initial Report of RTOG 9601: a phase III trial in prostate cancer: anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) improves freedom from progression and reduces the incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, n0 disease, and elevated PSA levels,” International Journal of Radiation Oncology, Biology, Physics, vol. 78, no. 3, supplement, p. S27, 2010. View at Google Scholar
  6. C. J. Tyrrell, H. Payne, T. L. J. Tammela et al., “Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia,” International Journal of Radiation Oncology Biology Physics, vol. 60, no. 2, pp. 476–483, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Perdonà, R. Autorino, S. De Placido et al., “Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial,” Lancet Oncology, vol. 6, no. 5, pp. 295–300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Boccardo, A. Rubagotti, M. Battaglia et al., “Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer,” Journal of Clinical Oncology, vol. 23, no. 4, pp. 808–815, 2005. View at Publisher · View at Google Scholar · View at Scopus